Central Lab

Central Lab Market Outlook

The global Central Lab Market size is projected to reach USD 8.2 billion by 2035, growing at a CAGR of 7.5% from 2025 to 2035. This growth is primarily driven by the increasing demand for advanced diagnostic techniques, a surge in chronic diseases, and the rising number of clinical trials globally. The trend towards outsourcing laboratory services to improve efficiency and reduce operational costs in healthcare facilities is also significantly contributing to the market's expansion. Additionally, technological advancements in laboratory equipment and increasing investments in research and development activities are further fueling market growth. Furthermore, the rising emphasis on preventive healthcare is expected to bolster the demand for laboratory services.

Growth Factor of the Market

One of the primary growth factors for the Central Lab Market is the increasing prevalence of chronic diseases such as diabetes, cancer, and cardiovascular disorders, which necessitate extensive laboratory testing for accurate diagnosis and monitoring. Additionally, the rising geriatric population, which is more susceptible to these diseases, is further driving market demand. There is also a growing trend towards personalized medicine, which requires comprehensive laboratory testing to tailor treatments to individual patient needs. The expansion of the pharmaceutical and biotechnology industries is contributing to the demand for laboratory services, as new drug development initiatives require extensive testing and validation. Furthermore, advancements in technology, such as automation in laboratories and the integration of artificial intelligence, are enhancing operational efficiency and improving diagnostic accuracy, making central labs more attractive to end users.

Key Highlights of the Market

• The Central Lab Market is projected to reach USD 8.2 billion by 2035.
• The market is expected to grow at a CAGR of 7.5% from 2025 to 2035.
• Increasing prevalence of chronic diseases is a significant driver for the market.
• Technological advancements are enhancing laboratory efficiency and diagnostic accuracy.
• The trend towards outsourcing laboratory services is gaining momentum among healthcare providers.

By Service Type

Clinical Chemistry Testing:

Clinical chemistry testing is a vital segment of the Central Lab Market, which involves the analysis of bodily fluids such as blood and urine to assess metabolic functions and detect diseases. This type of testing is in high demand due to its ability to provide critical information regarding patient health status, organ function, and the presence of various medical conditions. The rise in the prevalence of conditions such as diabetes and liver diseases is further boosting the market for clinical chemistry testing. Moreover, technological advancements in analytical equipment and the introduction of automated systems are enhancing the accuracy and efficiency of these tests, making them indispensable in clinical settings.

Microbiology Testing:

Microbiology testing plays a crucial role in diagnosing infections and monitoring the efficacy of antimicrobial treatments. This segment encompasses a wide range of tests, including culture and sensitivity tests, which are essential for identifying pathogens and determining appropriate therapies. The growing incidence of infectious diseases, driven by factors such as urbanization, global travel, and antibiotic resistance, is significantly propelling the demand for microbiology testing. Additionally, advancements in molecular diagnostics and rapid testing technologies are creating new opportunities within this segment, facilitating quicker diagnosis and improving patient outcomes.

Hematology Testing:

The hematology testing segment involves analyzing blood components to diagnose blood disorders, monitor therapy, and evaluate overall health. This segment is witnessing substantial growth due to the rising prevalence of blood-related conditions such as anemia and hemophilia. Furthermore, the increasing adoption of automated hematology analyzers is enhancing the efficiency and accuracy of testing, thus attracting healthcare providers to utilize central laboratories. The continuous development of new hematology tests and the integration of advanced technologies are also contributing to the growth of this segment, expanding its application in various clinical settings.

Immunology Testing:

Immunology testing is essential for diagnosing autoimmune diseases, allergies, and infectious diseases by assessing the body's immune response. The growing awareness of immune-related conditions and the expanding field of immunotherapy are driving the demand for immunology testing services. Innovations such as multiplex assays and point-of-care testing are becoming increasingly popular, enabling faster and more comprehensive evaluations. The rising investments in research and advancements in diagnostic technologies are expected to bolster this segment further, making it a key area of growth within the Central Lab Market.

Molecular Diagnostics:

Molecular diagnostics has emerged as a transformative segment in the Central Lab Market, offering highly specific and sensitive testing methods that detect genetic material and biomarkers for various diseases. This segment is witnessing rapid growth due to advancements in next-generation sequencing and PCR technologies, which enable timely and accurate disease detection. The rising prevalence of genetic disorders, coupled with the growing demand for personalized medicine, is fueling the adoption of molecular diagnostics. Additionally, the COVID-19 pandemic has further accelerated the acceptance of molecular testing, highlighting its importance in infectious disease management and surveillance.

By End User

Hospitals:

Hospitals are among the primary end users of central laboratory services, relying on accurate and timely laboratory results for effective patient care. The growing patient volume and complexity of cases in hospitals necessitate the use of advanced diagnostic techniques, thereby driving the demand for central lab services. Furthermore, hospitals are increasingly outsourcing laboratory testing to central labs to improve operational efficiency, reduce turnaround times, and lower costs. This trend is particularly prominent in regions with limited hospital resources, where central labs can provide specialized testing capabilities that enhance the overall quality of healthcare delivery.

Pharmaceutical Companies:

Pharmaceutical companies are significant end users of central laboratory services, particularly for drug development, clinical trials, and regulatory compliance. Central labs provide essential testing services required to evaluate drug efficacy and safety, facilitating the approval process for new therapeutics. The increasing number of clinical trials and the growing emphasis on personalized medicine are driving the demand for laboratory services within the pharmaceutical sector. Moreover, the collaboration between pharmaceutical companies and central labs is becoming more common, as it allows for access to specialized testing capabilities and expertise that can expedite drug development timelines.

Clinical Research Organizations:

Clinical Research Organizations (CROs) play a vital role in the Central Lab Market by providing outsourced research services to the pharmaceutical and biotechnology sectors. CROs frequently utilize central laboratory services to conduct clinical trials, ensuring that they have access to comprehensive and reliable testing facilities. The increasing trend of outsourcing clinical trials to CROs, along with the rising complexity of clinical studies, is boosting the demand for central lab services. Additionally, the ability of CROs to leverage advanced technologies and analytics enhances the quality of data generated during trials, making central labs an indispensable partner in clinical research.

Academic & Research Institutes:

Academic and research institutes are significant contributors to the Central Lab Market, as they require laboratory services for various research projects and education. These institutions often collaborate with central labs to access specialized testing capabilities and equipment that may not be available in-house. The growing focus on research and development in the healthcare sector is driving the demand for laboratory services from academic institutions. Moreover, the increasing funding for medical research and the emphasis on innovation in diagnostics are leading to a higher reliance on central laboratories to support academic and research initiatives.

Others:

Other end users, including governmental and regulatory bodies, diagnostic laboratories, and private clinics, also contribute to the Central Lab Market. These entities require laboratory services for public health monitoring, disease control, and routine diagnostics. The growing need for precise and comprehensive testing in various healthcare settings is driving the demand for central lab services among these end users. Additionally, as healthcare systems evolve to address emerging health challenges, the reliance on centralized laboratory services is expected to increase, further augmenting the market landscape.

By Test Type

Routine Tests:

Routine tests are fundamental components of the Central Lab Market, encompassing standard diagnostic procedures that are commonly performed to monitor health and diagnose diseases. These tests, which include complete blood counts, metabolic panels, and lipid profiles, are essential for providing baseline health information and ongoing patient monitoring. The high volume and frequency of routine tests drive their market demand, particularly in primary care settings and hospitals. As healthcare providers increasingly prioritize preventive care and early disease detection, the importance of routine laboratory testing continues to grow, solidifying its role in the central laboratory landscape.

Specialized Tests:

Specialized tests represent a critical segment of the Central Lab Market, focusing on specific diagnostic needs that require advanced methodologies and technologies. These tests are typically conducted for patients with complex conditions or those requiring targeted therapies. The rising prevalence of chronic diseases and the demand for precision medicine are driving the growth of specialized testing services. Additionally, technological advancements in laboratory equipment and testing techniques are enhancing the accuracy and reliability of specialized tests, making them indispensable for healthcare providers seeking to provide personalized treatment options for patients.

Esoteric Tests:

Esoteric tests are a niche segment within the Central Lab Market that involves complex and rare diagnostic procedures, often requiring unique expertise and advanced technology. These tests are typically utilized for rare diseases, genetic disorders, and other specialized medical concerns. The increasing demand for esoteric testing is driven by the rise in genetic and rare diseases, along with the growing emphasis on personalized medicine. As more healthcare providers seek to offer unique diagnostic solutions to their patients, the market for esoteric tests is expected to expand, providing significant opportunities for central laboratories.

Endocrinology Tests:

Endocrinology tests are essential for diagnosing and monitoring conditions related to hormonal imbalances, such as diabetes, thyroid disorders, and adrenal issues. The rising incidence of endocrine disorders is driving the demand for laboratory testing within this specialty. Additionally, advancements in testing methodologies, including immunoassays and molecular diagnostics, are enhancing the precision and reliability of endocrinology tests. As the global focus on metabolic health increases, the demand for these specialized tests is expected to grow, creating new opportunities for central laboratories to expand their service offerings.

Infectious Disease Tests:

Infectious disease tests are a crucial segment of the Central Lab Market, aimed at diagnosing and monitoring various infectious agents, such as bacteria, viruses, and parasites. The increase in global travel, population density, and antibiotic resistance has led to a surge in infectious diseases, driving the demand for laboratory services in this area. Additionally, the COVID-19 pandemic has highlighted the importance of rapid and accurate infectious disease testing, further propelling market growth. The ongoing advancements in molecular diagnostics and point-of-care testing technologies are expected to enhance the capabilities of central laboratories in providing timely and accurate infectious disease diagnostics.

By Sample Type

Blood:

Blood samples are the most commonly utilized specimen type in the Central Lab Market, as they provide crucial information regarding a patient's health status and enable a wide range of diagnostic tests. Blood testing is fundamental for routine health screenings, disease diagnosis, and therapeutic monitoring. The high volume of blood tests performed daily in hospitals and clinics drives the demand for central laboratories. Additionally, advancements in blood collection and processing technologies are improving the efficiency and accuracy of blood testing, further solidifying its significance in the laboratory landscape.

Urine:

Urine samples are another critical specimen type in the Central Lab Market, commonly used for a variety of diagnostic tests, including renal function assessments, drug screening, and metabolic evaluations. Urinalysis is a routine procedure that provides valuable insights into a patient's health and is often used for early disease detection. The growing prevalence of renal diseases and the demand for drug monitoring are driving the market for urine testing services. Furthermore, advancements in urine collection and analysis techniques are enhancing the reliability and efficiency of urine tests, making them a vital component of central laboratory services.

Saliva:

Saliva samples are gaining traction as a non-invasive specimen type for various diagnostic tests, including hormone level assessments and genetic testing. The increasing acceptance of saliva testing in both clinical and research settings is driving market growth, as it offers a convenient alternative to traditional blood and urine sampling. Saliva testing is particularly valuable for monitoring hormonal changes and assessing oral health. Additionally, advancements in saliva collection and analytical methods are enhancing the accuracy and reliability of test results, further promoting the adoption of saliva testing in central laboratories.

Tissue:

Tissue samples are essential for diagnostic testing in the Central Lab Market, particularly in oncology and pathology. These samples are used to assess cellular morphology, detect malignancies, and evaluate treatment responses. The rising incidence of cancer and the growing need for accurate diagnostics are driving the demand for tissue testing services. Innovations in histopathological techniques and molecular diagnostics are enhancing the capabilities of central laboratories to provide precise tissue analysis. As the focus on personalized medicine increases, the role of tissue testing in guiding treatment decisions is expected to expand, creating new opportunities for laboratory services.

Others:

Other sample types, including fecal samples, hair, and other biological specimens, are also utilized in the Central Lab Market for specific diagnostic purposes. These samples may be used for various tests, including gastrointestinal assessments, drug testing, and genetic analyses. The growing demand for comprehensive testing services is driving the utilization of diverse sample types within central laboratories. As advances in testing methodologies and technologies continue to evolve, the opportunities for utilizing alternative sample types are expanding, providing central labs with additional avenues to enhance their service offerings.

By Region

The North American Central Lab Market holds a significant share, driven by the presence of advanced healthcare infrastructure, robust research activities, and a high prevalence of chronic diseases. The market in this region is expected to grow at a CAGR of 7.3% during the forecast period, fueled by an increasing demand for laboratory services from hospitals and pharmaceutical companies. The United States, in particular, is witnessing substantial growth in clinical trials and laboratory outsourcing, leading to an increased reliance on central laboratories for accurate and timely diagnostic services. Moreover, government initiatives aimed at improving healthcare access and outcomes are contributing to market expansion in this region.

In Europe, the Central Lab Market is also experiencing notable growth, propelled by the increasing emphasis on research and development activities, particularly in the pharmaceutical and biotechnology sectors. The European market is anticipated to grow at a CAGR of 6.9% during the forecast period, driven by the rising prevalence of chronic diseases and the need for advanced diagnostic solutions. Additionally, the growing trend of personalized medicine and the adoption of automation in laboratories are influencing market dynamics in this region. Countries like Germany, France, and the United Kingdom are leading the market due to their well-established healthcare systems and investments in research initiatives.

Opportunities

The Central Lab Market is poised to capitalize on numerous opportunities, particularly in the realm of technological advancements and innovation. With the rise of automation, artificial intelligence, and digital health solutions, central laboratories can enhance their operational efficiency and improve diagnostic accuracy. The integration of advanced technologies such as machine learning and predictive analytics into laboratory processes can streamline workflows, reduce turnaround times, and optimize resource utilization. Additionally, the development of telemedicine and remote testing services presents new avenues for central labs to expand their reach and provide services to underserved populations. By leveraging these technologies, central laboratories can not only improve patient outcomes but also drive profitability and growth in an increasingly competitive market.

Another significant opportunity lies in the expansion of laboratory services into emerging markets. As healthcare systems in developing regions evolve and demand for diagnostic services increases, central laboratories can play a critical role in addressing these needs. The rising prevalence of infectious diseases, coupled with the increasing focus on preventive healthcare, presents a unique opportunity for central labs to establish a presence in these regions. By forming strategic partnerships with local healthcare providers and investing in capacity-building initiatives, central laboratories can effectively navigate the challenges of entering new markets while contributing to improved health outcomes in underserved populations.

Threats

The Central Lab Market faces several threats, including increasing competition from smaller laboratories and point-of-care testing services. As the demand for laboratory services continues to grow, new entrants are emerging in the market, offering specialized and often more affordable testing options. This increased competition can put pressure on pricing and margins for established central laboratories, necessitating the need for innovation and differentiation in service offerings. Additionally, shifts in regulatory landscapes and reimbursement policies can pose challenges for central labs, as they navigate complex compliance requirements and adapt to changing financial dynamics. Moreover, the potential for economic downturns can impact healthcare spending, leading to reduced demand for laboratory services in the broader healthcare ecosystem.

Another key restraining factor for market growth is the potential for supply chain disruptions, particularly in the context of global health emergencies. The COVID-19 pandemic has highlighted vulnerabilities in supply chains for laboratory reagents, consumables, and equipment. Such disruptions can lead to delays in testing, increased costs, and challenges in maintaining service quality. Additionally, the growing emphasis on cost containment within healthcare systems can hinder the willingness of providers to outsource laboratory services, further impacting the demand for central labs. To mitigate these risks, central laboratories must diversify their supply chains, invest in contingency planning, and focus on building resilient operational models that can withstand external shocks.

Competitor Outlook

• LabCorp
• Quest Diagnostics
• Eurofins Scientific
• Charles River Laboratories
• Covance
• Medpace
• Syneos Health
• Laboratory Corporation of America
• Genomic Health
• Thermo Fisher Scientific
• Roche Diagnostics
• BioReference Laboratories
• Abbott Laboratories
• PerkinElmer
• OPKO Health

The competitive landscape of the Central Lab Market is characterized by a diverse range of players, including established multinational corporations and specialized regional laboratories. Major players such as LabCorp and Quest Diagnostics dominate the market, leveraging their extensive networks, advanced technologies, and comprehensive service offerings to maintain a competitive edge. These companies are continuously investing in research and development to enhance their testing capabilities and improve operational efficiencies. Additionally, strategic partnerships and collaborations with healthcare providers, pharmaceutical companies, and academic institutions are becoming increasingly common as players seek to expand their market reach and improve service delivery.

Emerging players and specialized laboratories are also gaining traction in the Central Lab Market by focusing on niche testing services and innovative methodologies. Companies such as Eurofins Scientific and Charles River Laboratories are carving out their market segments by providing unique testing solutions and expertise in specific therapeutic areas. The competition is further intensified by the growing trend toward point-of-care testing, which is changing the dynamics of laboratory services. As healthcare providers seek faster and more convenient testing options, traditional central laboratories must adapt their offerings and enhance their value propositions to remain competitive.

Key companies in the Central Lab Market, such as Thermo Fisher Scientific and Roche Diagnostics, are actively pursuing growth strategies that include mergers and acquisitions to expand their portfolios and gain access to new technologies. These companies are focusing on enhancing their capabilities in molecular diagnostics, automation, and digital health solutions to meet the evolving needs of healthcare providers. Furthermore, the increasing emphasis on personalized medicine and precision diagnostics is prompting major players to invest in innovative testing methodologies and genomic technologies, positioning themselves to capitalize on emerging trends within the market. As competition continues to evolve, companies must remain agile and responsive to changing market dynamics to sustain their growth trajectories.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Covance
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 LabCorp
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Medpace
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 OPKO Health
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 PerkinElmer
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Syneos Health
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Genomic Health
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Quest Diagnostics
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Roche Diagnostics
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Abbott Laboratories
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Eurofins Scientific
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Thermo Fisher Scientific
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 BioReference Laboratories
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Charles River Laboratories
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Laboratory Corporation of America
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Central Lab Market, By End User
    • 6.1.1 Hospitals
    • 6.1.2 Pharmaceutical Companies
    • 6.1.3 Clinical Research Organizations
    • 6.1.4 Academic & Research Institutes
    • 6.1.5 Others
  • 6.2 Central Lab Market, By Test Type
    • 6.2.1 Routine Tests
    • 6.2.2 Specialized Tests
    • 6.2.3 Esoteric Tests
    • 6.2.4 Endocrinology Tests
    • 6.2.5 Infectious Disease Tests
    • 6.2.6 Others
  • 6.3 Central Lab Market, By Sample Type
    • 6.3.1 Blood
    • 6.3.2 Urine
    • 6.3.3 Saliva
    • 6.3.4 Tissue
    • 6.3.5 Others
  • 6.4 Central Lab Market, By Service Type
    • 6.4.1 Clinical Chemistry Testing
    • 6.4.2 Microbiology Testing
    • 6.4.3 Hematology Testing
    • 6.4.4 Immunology Testing
    • 6.4.5 Molecular Diagnostics

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Central Lab Market by Region
  • 10.3 Asia Pacific - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 India
      • 10.3.1.2 China
      • 10.3.1.3 Japan
      • 10.3.1.4 South Korea
  • 10.4 Latin America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 Brazil
      • 10.4.1.2 Argentina
      • 10.4.1.3 Mexico
  • 10.5 North America - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 USA
      • 10.5.1.2 Canada
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Central Lab market is categorized based on

By Service Type

• Clinical Chemistry Testing
• Microbiology Testing
• Hematology Testing
• Immunology Testing
• Molecular Diagnostics

By End User

• Hospitals
• Pharmaceutical Companies
• Clinical Research Organizations
• Academic & Research Institutes
• Others

By Test Type

• Routine Tests
• Specialized Tests
• Esoteric Tests
• Endocrinology Tests
• Infectious Disease Tests
• Others

By Sample Type

• Blood
• Urine
• Saliva
• Tissue
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• LabCorp
• Quest Diagnostics
• Eurofins Scientific
• Charles River Laboratories
• Covance
• Medpace
• Syneos Health
• Laboratory Corporation of America
• Genomic Health
• Thermo Fisher Scientific
• Roche Diagnostics
• BioReference Laboratories
• Abbott Laboratories
• PerkinElmer
• OPKO Health